These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 31875970)

  • 1. Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
    Job S; Rapoud D; Dos Santos A; Gonzalez P; Desterke C; Pascal G; Elarouci N; Ayadi M; Adam R; Azoulay D; Castaing D; Vibert E; Cherqui D; Samuel D; Sa Cuhna A; Marchio A; Pineau P; Guettier C; de Reyniès A; Faivre J
    Hepatology; 2020 Sep; 72(3):965-981. PubMed ID: 31875970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma.
    Lozzi I; Arnold A; Barone M; Johnson JC; Sinn BV; Eschrich J; Gebert P; Wang R; Hu M; Feldbrügge L; Schirmeier A; Reutzel-Selke A; Malinka T; Krenzien F; Schöning W; Modest DP; Pratschke J; Sauer IM; Felsenstein M
    Oncoimmunology; 2024; 13(1):2406052. PubMed ID: 39359389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of inflammatory subtypes in intrahepatic cholangiocellular carcinoma.
    Gao B; Wang Y; Zhang X; Jiang H; Han F; Li C; Lu S
    J Transl Med; 2024 Aug; 22(1):730. PubMed ID: 39103879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.
    Shimonishi T; Isse K; Shibata F; Aburatani I; Tsuneyama K; Sabit H; Harada K; Miyazaki K; Nakanuma Y
    Hepatology; 2000 Oct; 32(4 Pt 1):761-9. PubMed ID: 11003620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
    J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type.
    Aishima S; Oda Y
    J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):94-100. PubMed ID: 25181580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment.
    Pu X; Li L; Xu F; Wang Z; Fu Y; Wu H; Ren J; Chen J; Sun B
    J Cancer Res Clin Oncol; 2024 Aug; 150(8):403. PubMed ID: 39198311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrahepatic cholangiocarcinoma: new insights in pathology.
    Sempoux C; Jibara G; Ward SC; Fan C; Qin L; Roayaie S; Fiel MI; Schwartz M; Thung SN
    Semin Liver Dis; 2011 Feb; 31(1):49-60. PubMed ID: 21344350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma.
    Chen S; Xie Y; Cai Y; Hu H; He M; Liu L; Liao C; Wang Y; Wang J; Ren X; Zeng Q; Peng H; Shen S; Li S; Li D; Lai J; Peng B; Ren J; Kuang M; Peng S
    Clin Cancer Res; 2022 May; 28(9):1896-1910. PubMed ID: 34526363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma.
    Hua S; Gu X; Jin H; Zhang X; Liu Q; Yang J
    Biomed Pharmacother; 2024 Aug; 177():117080. PubMed ID: 38972151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma.
    Hayashi A; Misumi K; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
    Am J Surg Pathol; 2016 Aug; 40(8):1021-30. PubMed ID: 27259014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
    Sia D; Hoshida Y; Villanueva A; Roayaie S; Ferrer J; Tabak B; Peix J; Sole M; Tovar V; Alsinet C; Cornella H; Klotzle B; Fan JB; Cotsoglou C; Thung SN; Fuster J; Waxman S; Garcia-Valdecasas JC; Bruix J; Schwartz ME; Beroukhim R; Mazzaferro V; Llovet JM
    Gastroenterology; 2013 Apr; 144(4):829-40. PubMed ID: 23295441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy-related gene expression classification defines three molecular subtypes with distinct clinical and microenvironment cell infiltration characteristics in colon cancer.
    Zhu S; Wu Q; Zhang B; Wei H; Li B; Shi W; Fang M; Zhu S; Wang L; Lang Zhou Y; Dong Y
    Int Immunopharmacol; 2020 Oct; 87():106757. PubMed ID: 32769067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma.
    Sun BY; Yang ZF; Wang ZT; Liu G; Zhou C; Zhou J; Fan J; Gan W; Yi Y; Qiu SJ
    World J Surg Oncol; 2023 Mar; 21(1):90. PubMed ID: 36899373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.
    Xue R; Chen L; Zhang C; Fujita M; Li R; Yan SM; Ong CK; Liao X; Gao Q; Sasagawa S; Li Y; Wang J; Guo H; Huang QT; Zhong Q; Tan J; Qi L; Gong W; Hong Z; Li M; Zhao J; Peng T; Lu Y; Lim KHT; Boot A; Ono A; Chayama K; Zhang Z; Rozen SG; Teh BT; Wang XW; Nakagawa H; Zeng MS; Bai F; Zhang N
    Cancer Cell; 2019 Jun; 35(6):932-947.e8. PubMed ID: 31130341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.
    Zeng TM; Pan YF; Yuan ZG; Chen DS; Song YJ; Gao Y
    Front Immunol; 2022; 13():943066. PubMed ID: 36159865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.
    Higashi M; Yonezawa S; Ho JJ; Tanaka S; Irimura T; Kim YS; Sato E
    Hepatology; 1999 Dec; 30(6):1347-55. PubMed ID: 10573510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-κB pathway-mediated inflammatory responses.
    Liu B; Yan S; Jia Y; Ma J; Wu S; Xu Y; Shang M; Mao A
    FEBS J; 2016 Oct; 283(20):3839-3850. PubMed ID: 27616304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-Sectional Imaging of Intrahepatic Cholangiocarcinoma: Development, Growth, Spread, and Prognosis.
    Seo N; Kim DY; Choi JY
    AJR Am J Roentgenol; 2017 Aug; 209(2):W64-W75. PubMed ID: 28570102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.